Clinicopathological difference between invasive pancreatic duct cancer and distal bile duct cancer of the pancreas head after pancreatectoduodenectomy

Masahide Ikeguchi, Kanenori Endo

ABSTRACT

Aims: The only curative treatment for patients with invasive pancreatic duct cancer (IPDC) and distal bile duct cancer (DBDC) of the pancreas head is pancreatectoduodenectomy (PD). However, the clinicopathological difference between IPDC and DBDC after PD has not been thoroughly discussed. In this study, we retrospectively analyzed the clinical and pathological difference between IPDC and DBDC in patients who underwent PD. Methods: Sixty-six patients who underwent curative PD were enrolled (IPDC, n = 35; DBDC, n = 31). Preoperative, intraoperative, and postoperative parameters and pathological factors (stages, lymph node metastasis, lymphatic invasion, vascular invasion, and perineural invasion) were compared. Results: Jaundice was frequently detected and preoperative biliary drainage was frequently performed in patients with DBDC (60.5% and 90.3%, respectively). Additionally, the preoperative serum total bilirubin concentration and C-reactive protein/albumin ratio were higher in patients with DBDC than IPDC. As a result, the occurrence of postoperative pancreatic fistula occurred more frequently in patients with DBDC. In contrast, lymph node metastasis, lymphatic invasion, and vascular invasion were detected more frequently in patients with IPDC. The overall 5-year survival rate of the 35 patients with IPDC (13.4%) was much worse than that of the 31 patients with DBDC (52.3%, p < 0.001).

Conclusion: The oncological characteristics of IPDC are much different from those of DBDC. More effective treatment should be started in patients with IPDC as soon as possible.

Keywords: Distal bile duct cancer, Invasive pancreatic duct cancer, Pancreatectoduodenectomy, Prognosis

INTRODUCTION

Patients with invasive pancreatic duct cancer (IPDC) of the pancreas head or distal bile duct cancer (DBDC) present similar clinical manifestations, such as jaundice and abdominal pain. In general, the diagnosis of IPDC and DBDC is based on histomorphological evaluation of endoscopic biopsy specimens using pretreatment endoscopic retrograde cholangiopancreatography (ERCP). The histological type of both pancreatic and biliary tract cancers is typically adenocarcinoma [1, 2]. Because of their anatomical and histopathological similarity, the distinction between IPDC and DBDC is sometimes difficult before treatment, even with the use of ERCP, computed tomography, or magnetic resonance imaging [3].

However, the treatment method is simple because surgical resection is the only established potentially curative treatment for patients with IPDC and DBDC.
However, the clinicopathological differences between IPDC and DBDC after pancreaticoduodenectomy (PD) have not been thoroughly discussed. In this study, we retrospectively analyzed the clinical and pathological differences between IPDC and DBDC in patients who underwent PD.

MATERIALS AND METHODS

Patients

From 2006 to 2018, 102 patients who were diagnosed with operable periampullary or pancreas head cancer underwent PD at Tottori Prefectural Central Hospital. The preoperative locations of tumors were diagnosed by computed tomography, magnetic resonance imaging, and retrograde cholangiopancreatography using ERCP. Of these patients, we enrolled 35 patients with IPDC and 31 patients with DBDC (histopathologically confirmed) in the present study. In the present study, we focused on the clinicopathological differences between IPDC and DBDC, the remaining 36 patients diagnosed as duodenal cancer including cancer arising from papilla Vater excluded from this study. These 66 patients (35 patients with IPDC and 31 patients with DBDC) underwent curative PD (no residual tumors macroscopically). The patients were followed up at Tottori Prefectural Central Hospital until October 2019. No patients received chemotherapy or radiation therapy before the operation. Informed consent for medical treatment and use of clinical data from the medical records were obtained from all patients. This study was approved by the ethics review board of Tottori Prefectural Central Hospital (approval number: 2019-57).

Preoperative data

We recorded the patients’ preoperative parameters, including the occurrence of jaundice and a history of smoking or alcohol intake. Blood samples were routinely taken from each patient before the operation. The fasting blood sugar level, serum amylase level, serum total bilirubin level (the preoperative bilirubin was after drainage), serum albumin level, C-reactive protein level, total lymphocyte count, and tumor marker levels (carcinoembryonic antigen and carbohydrate antigen 19-9) were recorded. The C-reactive protein/albumin ratio (CAR), neutrophil/lymphocyte ratio (NLR), and prognostic nutritional index (PNI) were calculated preoperatively. The PNI was calculated using the following formula: 10 × serum albumin concentration (g/dL) + 0.005 × lymphocyte count (cells/mm³) in the peripheral blood [4]. The CAR has been used in combination with other parameters to not only diagnose chronic inflammation but also assess the nutritional status of patients with cancer. Additionally, the pretreatment CAR has been shown to be a significant prognostic indicator in various carcinomas [5–7]. Also, the NLR and PNI are markers of chronic systemic inflammation and the patients’ immune status and nutritional condition [8–10]. We analyzed and compared these CAR, NLR, and PNI (prognostic markers of cancer patients) in different type of carcinomas.

Surgical procedures and intraoperative parameters

All patients underwent open laparotomy. Reconstruction after PD with or without partial resection of the portal vein was performed by Child’s method. Pancreaticojejunostomy was performed and an internal short stent was placed across the pancreaticojejunostomy, but no stent was placed following choledochojejunostomy. The operation time and intraoperative blood loss were compared between the two groups.

Pathological parameters

Clinical and pathological staging of IPDC and DBDC was performed using the American Joint Committee on Cancer TNM staging system, 6th edition [11]. The positive cases of lymphatic invasion, vascular invasion, and perineural invasion of tumor cells were compared between the two groups.

Postoperative parameters

Postoperative complications were analyzed by reviewing the patients’ clinical data. The severity of postoperative complications was graded according to the Clavien–Dindo classification [12]. Clavien–Dindo grade ≥III complications were considered major complications. Postoperative pancreatic fistula (POPF) was defined and classified by the international study group of pancreatic fistula (ISGPF) [13]. Grade B (symptomatic, clinically apparent, and requires diagnostic evaluation and specific medical treatment or prolonged drainage for longer than three weeks) and grade C (requires a major change in clinical management or deviation from the normal clinical pathway) were considered as POPF in this study. The occurrence of POPF, the hospital stay, operation-related death, and overall survival (OS) were compared between the groups.

Statistical analysis

Differences between two normally distributed parameters were compared using the χ² test and Fisher’s exact probability test. The Mann–Whitney U test was used to compare differences between two parameters with non-normal distributions. Long-term OS was calculated using the Kaplan–Meier method, and the prognostic difference between the two groups was compared using the log-rank test. All data were analyzed by StatView software (Abacus Concepts, Inc., Berkeley, CA, USA). A p value of <0.05 was considered statistically significant.
RESULTS

The patients' preoperative details are shown in Tables 1 and 2. Jaundice was frequently detected and preoperative biliary drainage was frequently performed in patients with DBDC (60.5% and 90.3%, respectively). Thus, the preoperative serum total bilirubin concentration and CAR were higher in patients with DBDC than IPDC. Glucose tolerance abnormalities were more frequently detected in patients with IPDC than DBDC. In contrast, the mean preoperative serum carbohydrate antigen 19-9 level was significantly higher in patients with DBDC than IPDC. In both groups, accurate preoperative diagnoses were obtained in >85% of patients (Table 1).

Pathologically, lymph node metastasis, lymphatic invasion, and vascular invasion were detected more frequently in patients with IPDC than DBDC. However, the rate of perineural invasion was similar in both groups. Thus, the pathological stages were more advanced in patients with IPDC than DBDC (Table 3).

No difference was found in the operation time or intraoperative blood loss between the two groups, but combined partial resection of the portal vein was performed more frequently in patients with IPDC than DBDC. Major postoperative complications occurred in 34/66 (51.5%) patients (IPDC, 14/35 [40.0%) and DBDC, 20/31 [64.5%]). Among the complications, POPF occurred more frequently in patients with DBDC than IPDC. Four patients (IPDC, n = 2; DBDC, n = 2) died of postoperative peritonitis secondary to leakage at the pancreaticojejunostomy site at one month (n = 2), two months (n = 1), and eight months (n = 1) postoperatively. Thus, the operative mortality rate in our series was 6.1% (Table 4). The OS rates, including the deaths from operative complications, were quite different between the two groups (Figure 1). The overall 5-year survival rate of the 31 patients with DBDC (52.3%) was much better than that of the 35 patients with IPDC (13.4%, p < 0.001).

Table 1: Preoperative clinical differences between the two groups

|                                | IPDC (n = 35) | DBDC (n = 31) | p       |
|--------------------------------|---------------|---------------|---------|
| Gender (male/female)           | 22/13         | 22/9          | 0.485   |
| Mean age (years, SD)           | 72.5 (8.1)    | 75.4 (8.2)    | 0.113   |
| Mean BMI (SD)                  | 22.3 (3.4)    | 22.3 (2.9)    | 0.512   |
| Both consumption of tobacco and alcohol (yes, %) | 10 (28.6%)    | 11 (35.5%)    | 0.547   |
| Occurrence of jaundice (yes, %) | 15 (39.5%)    | 23 (60.5%)    | 0.01    |
| Preoperative biliary drainage (yes, %) | 18 (51.4%)    | 28 (90.3%)    | 0.001   |
| Accurate preoperative diagnosis (yes, %) | 30 (85.7%)    | 29 (93.5%)    | 0.536   |

BMI: body mass index, DBDC: distal bile duct cancer, IPDC: invasive pancreatic duct cancer, SD: standard deviation.

DISCUSSION

IPDC and DBDC are major malignant tumors arising from the pancreas head, and the histological type of both cancers is adenocarcinoma. Although the two tumors have many similarities, their oncological behaviors are quite different. Yokoyama et al. [14] reported that the incidence rates of overall morbidity, infectious complications, and pancreatic fistula were significantly higher in patients with DBDC than IPDC. They concluded that the main reasons for this difference were a significantly smaller main pancreatic duct diameter and higher incidence of a soft pancreas (95% vs. 29%) in patients with DBDC than IPDC. Indeed, in our study, POPF more frequently occurred in patients with DBDC (64.5%) than IPDC (31.4%), and the difference was significant (p < 0.007). However, we could not prove the correlation between the occurrence of POPF and the pancreatic duct diameter or incidence of a soft pancreas individually because we did not check these parameters at the time of the operations. However, we found that obstructive jaundice and preoperative biliary drainage were more frequent and that the preoperative serum total bilirubin concentration and CAR were significantly higher in patients with DBDC than IPDC. These facts indicate that high inflammation and a poor nutritional condition may continue until immediately before the operations. In cases with tumors of pancreas head, distal bile duct, and papilla Vater, we usually did endoscopic biopsy using ERCP, and at that time, when we decided obstruction of bile duct, we basically performed the stent insertion to bile duct to reduce serum bilirubin level and control inflammation of the bile duct in our department. However, in this study, we found high percentage of POPF in patients with DBDC. It is difficult to decide biliary drainage may cause the POPF or not. Further studies should be needed to improve the correlation between biliary drainage and the occurrence of POPF after PD, and we may change our strategy for biliary drainage in patients with obstructive jaundice.
Ikeguchi et al. indicated that early surgery following preoperative biliary drainage reduced the occurrence of POPF. Shin et al. [15] recommended the performance of PD within two weeks after biliary drainage in patients with obstructive jaundice. Notably, however, the prognosis of patients with IPDC is significantly worse than that of patients with DBDC. Kim et al. [16] reported that the 5-year OS rate of patients with DBDC was 50.3% and that of patients with IPDC was 13.0%, respectively (p < 0.001). Additionally, Pomianowska et al. [17] reported that the 5-year OS rate was 6% for IPDC and 26% for DBDC. The authors also reported that lymph node involvement was more frequently detected in IPDC (75%) than in DBDC (57%). In the present study, lymphatic invasion and vascular invasion were detected more frequently in patients

Table 2: Preoperative laboratory data between the two groups

|                         | IPDC (n = 35) | DBDC (n = 31) | p     |
|-------------------------|---------------|---------------|-------|
| Mean total bilirubin (mg/dL, SD) | 1.7 (1.8)     | 2.2 (2.5)     | 0.165 |
| Mean fasting blood sugar (mg/dL, SD) | 158.3 (70.9)  | 115.6 (22.7)  | 0.001 |
| Mean serum amylase (U/L, SD) | 108.1 (83.9)  | 106.6 (59.8)  | 0.375 |
| Mean CEA levels (ng/mL, SD) | 6.6 (8.3)     | 4.5 (2.6)     | 0.492 |
| Mean CA 19-9 levels (U/mL, SD) | 481.7 (646.4) | 744.6 (3677.9)| 0.003 |
| Mean CAR levels (SD) | 0.13 (0.23) | 0.53 (1.06) | 0.042 |
| Mean NLR levels (SD) | 2.3 (0.8) | 2.7 (2) | 0.883 |
| Mean PNI levels (SD) | 44.7 (6.9) | 43.8 (7.9) | 0.521 |
| CA 19-9: carbohydrate antigen 19-9, CAR: C-reactive protein/albumin ratio, CEA: carcinoembryonic antigen, DBDC: distal bile duct cancer, IPDC: invasive pancreatic duct cancer, NLR: neutrophil/lymphocyte ratio, PNI: prognostic nutritional index, SD: standard deviation.

Table 3: Pathological differences between the two groups

|                         | IPDC (n = 35) | DBDC (n = 31) | p     |
|-------------------------|---------------|---------------|-------|
| Tumor stage             |               |               |       |
| IA                      | 3             | 4             |       |
| IB                      | 0             | 6             | 0.012 |
| IIA                     | 5             | 5             |       |
| IIB                     | 23            | 9             |       |
| III                     | 4             | 7             |       |
| Positive of lymph node metastasis (%) | 26 (74.3) | 10 (32.3) | 0.001 |
| Positive of lymphatic invasion (%) | 30 (85.7) | 18 (58.1) | 0.012 |
| Positive of vascular invasion (%) | 33 (94.3) | 17 (54.8) | <0.001 |
| Positive of perineural invasion (%) | 29 (82.9) | 24 (77.4) | 0.579 |
| DBDC: distal bile duct cancer, IPDC: invasive pancreatic duct cancer.

Table 4: Intraoperative and postoperative differences between the two groups

|                         | IPDC (n = 35) | DBDC (n = 31) | p     |
|-------------------------|---------------|---------------|-------|
| Mean operation time (minutes, SD) | 376 (101.5) | 387.8 (116.9) | 0.7   |
| Partial resection of portal vein (number, %) | 6 (17.1) | 1 (3.2) | 0.067 |
| Mean intraoperative blood loss (mL, SD) | 946.7 (497) | 1146.1 (1049.9) | 0.829 |
| Blood transfusion (yes, %) | 11 (31.4) | 11 (35.5) | 0.656 |
| Occurrence of POPF (%) | 11 (31.4) | 11 (35.5) | 0.656 |
| Mean postoperative hospital stay (days, SD) | 37.7 (37.6) | 45.1 (39.4) | 0.385 |
| Operation-related death (%) | 2 (5.7) | 2 (6.5) | 0.9   |
| Overall 5-year survival rate (%) | 15.4% | 52.3% | <0.001 |
| DBDC: distal bile duct cancer, IPDC: invasive pancreatic duct cancer, POPF: postoperative pancreatic fistula, SD: standard deviation.

Figure 1: The 5-year overall survival rate of the 31 patients with DBDC (solid line) was much better than that of the 35 patients with IPDC (dotted line, p < 0.001).
with IPDC than DBDC. This difference in the invasive ability of cancer cells may underlie the prognostic difference between IPDC and DBDC. Gonzalez et al. [18] concluded that smaller tumor size, lower rate of margin positivity, earlier onset of symptoms, increased ease of total resection due to tumor location, and the relatively younger mean age of DBDC patients compared to IPDC patients may be the main reason of better prognosis of patients with DBDC. Few papers have described the biological differences between pancreatic cancer cells and cholangiocarcinoma cells. Takenami et al. [19] concluded that five proteins and two biomarker panels are promising for distinguishing pancreas head cancer from distal bile duct cancer. These biomarkers may help to distinguish IPDC from DBDC.

**CONCLUSION**

Even no significant difference in treatment strategy for patients with IPDC and DBDC, biological characteristics of IPDC much differ from DBDC. Thus, more effective treatment should be considered in patients with IPDC.

**REFERENCES**

1. Nakanuma Y, Sato Y, Harada K, Sasaki M, Xu J, Ikeda H. Pathological classification of intrahepatic cholangiocarcinoma based on a new concept. World J Hepatol 2010;2(12):419–27.

2. Blechacz B, Gores GJ. Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment. Hepatology 2008;48(1):308–21.

3. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol 2013;11(1):13–21.e1.

4. Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. [Article in Japanese]. Nihon Geka Gakkai Zasshi 1984;85(9):1001–5.

5. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol 2006;12(23):3746–50.

6. Hwang JE, Kim HN, Kim DE, et al. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurrent or metastatic gastric cancer. BMC Cancer 2011;11:489.

7. Chen Z, Shao Y, Fan M, et al. Prognostic significance of preoperative C-reactive protein: Albumin ratio in patients with clear cell renal cell carcinoma. Int J Clin Exp Pathol 2015;8(11):14893–900.

8. Ubukata H, Motohashi G, Tabuchi T, Nagata H, Konishi S, Tabuchi T. Evaluation of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 2010;102(7):742–7.

9. Nozoe T, Kohno M, Iguchi T, et al. The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today 2012;42(6):532–5.

10. Ikeguchi M, Urushibara SI, Shimoda R, Yamamoto M, Maeta Y, Ashida K. Inflammation-based prognostic scores and nutritional prognostic index in patients with locally-advanced unresectable colorectal cancer. World J Surg Oncol 2014;12:210.

11. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 6ed. New York: Springer; 2002.

12. Li Z, Bai B, Ji G, Li J, Zhao Q. Relationship between Clavien-Dindo classification and long-term survival outcomes after curative resection for gastric cancer: A propensity score-matched analysis. Int J Surg 2018;60:67–73.

13. Bassi C, Dervensis C, Butturini G, et al. Postoperative pancreatic fistula: An international study group (ISGPF) definition. Surgery 2005;138(1):8–13.

14. Yokoyama Y, Ebata T, Igami T, et al. Different clinical characteristics between distal cholangiocarcinoma and pancreatic head carcinoma with biliary obstruction. Pancreas 2017;46(10):1322–6.

15. Shin SH, Han IW, Ryu Y, Kim N, Choi DW, Heo JS. Optimal timing of pancreatoduodenectomy following preoperative biliary drainage considering major morbidity and postoperative survival. J Hepatobiliary Pancreat Sci 2019;26(10):449–58.

16. Kim K, Chie EK, Jang JY, et al. Prognostic significance of tumour location after adjuvant chemoradiotherapy for peripanillary adenocarcinoma. Clin Transl Oncol 2012;14(5):391–5.

17. Pomianowska E, Westgaard A, Mathisen Ø, Clausen OPF, Gladhaug IP. Prognostic relevance of number and ratio of metastatic lymph nodes in resected pancreatic, ampullary, and distal bile duct carcinomas. Ann Surg Oncol 2013;20(1):233–41.

18. Gonzalez RS, Bagci P, Basturk O, et al. Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas. Mod Pathol 2016;29(11):1358–69.

19. Takenami T, Maeda S, Karasawa H, et al. Novel biomarkers distinguishing pancreatic head Cancer from distal cholangiocarcinoma based on proteomic analysis. BMC Cancer 2019;19(1):318.

*********

**Acknowledgments**

We thank Angela Morben, DVM, ELS, from Edanz Group (https://en-author-services.edanzgroup.com/), for editing a draft of this manuscript.

**Author Contributions**

Masahide Ikeguchi – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Kanenori Endo – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Guarantor of Submission
The corresponding author is the guarantor of submission.

Source of Support
None.

Consent Statement
Written informed consent was obtained from the patient for publication of this article.

Conflict of Interest
Authors declare no conflict of interest.

Data Availability
All relevant data are within the paper and its Supporting Information files.

Copyright
© 2020 Masahide Ikeguchi et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
